Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1435 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

SuperGen Q3 revenues up

SuperGen posted a net income of $3.89m for the third quarter 2010, or $0.06 per diluted share, compared to $833,000 or $0.01 per diluted share, for the comparable

Trius Torezolid Phosphate gets USPTO patent

Trius said that Torezolid phosphate (TR-701) is currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI). Trius has licensed patents

Kadmon Pharma takes over Three Rivers Pharma

With this acquisition, Three Rivers is expected to serve as the commercial and operational cornerstone for Kadmon. Three Rivers is known to currently market several products for the

Amgen Q3 revenue remains unchanged

Adjusted net income decreased 14% to $1,313m for the third quarter of 2010, compared to $1,518m for the third quarter of 2009. The decrease in adjusted net income